- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02539459
Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE)
December 13, 2022 updated by: Fox Chase Cancer Center
A Phase II Study of Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus Therapy
The purpose of this research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs).
AMLs are the most common non-cancerous tumor of the kidney.
They are composed of blood vessels, muscle cells and fat cells.Everolimus is already an approved drug for several other diseases like kidney cancer, but is being studied now specifically to see if it is helpful for people with AML.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Primary Objective
1. To evaluate the efficacy and tolerability of everolimus in reducing tumor volume in sporadic AMLs as measured by dynamic contrast enhanced magnetic resonance imaging (DCE MRI), in patients who might otherwise be considered for active surgical or percutaneous intervention.
Secondary Objectives
- To evaluate health-related quality of life (HRQoL) in subjects treated with everolimus for sporadic AMLs.
- To assess the growth kinetics of sporadic AMLs in patients who have been treated with everolimus as part of the study and demonstrate an objective response as well as those who have been treated with everolimus during the study with a suboptimal or no response.
- To measure the rate of surgical or percutaneous (embolization) intervention at 1 year from day 1 of study.
- To assess the safety and tolerability of everolimus in patients with sporadic AML.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States
- Yale School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, United States
- Mayo Clinic
-
-
New York
-
New York, New York, United States
- Memorial Sloan Kettering
-
-
North Carolina
-
Durham, North Carolina, United States
- Duke University Health System
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, United States
- University of Pennsylvania
-
-
Texas
-
Houston, Texas, United States
- M D Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have a diagnosis of renal AML > 3 cm confirmed on pre-enrollment Dynamic Contrast Enhanced MRI (DCE-MRI)
- Must not have received any prior treatment for AML
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Absolute neutrophil count >= 1,500/ microliter (mcL)
- Hemoglobin >=10 g/dL
- Platelets >= 100,000/ mcL
- international normalized ratio (INR) <= 1.2 X Upper limit Normal (ULN)
- activated partial thromboplastin time (aPTT) <= 1.2 X ULN
- aspartate aminotransferase (AST) / alanine transaminase (ALT) <= 2.5 X ULN
- Total bilirubin <= 2.0mg/dL
- Renal Function epidermal growth factor receptor (eGFR) >= 30 mL/min via calculated creatinine clearance
- Fasting serum cholesterol <= 300 mg/dL OR <= 7.75 mmol/L AND fasting triglycerides <= 2.5x ULN.
Exclusion Criteria:
- History of tuberous sclerosis, LAM or any active malignancy
- Treatment with any other investigational agents for any other disease
- Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding or affect absorption of investigational product
- Active diarrhea of any grade.
- History of human immunodeficiency virus (HIV) infection, hepatitis B or C (screening for all three is mandatory prior to study); prior hepatitis C infection
- Presence of any active or ongoing infection.
- Any known uncontrolled underlying pulmonary disease by history, physical exam or if applicable pulmonary function test (PFTs)
- History of certain cardiovascular conditions within the past 6 months
- History of Class III or IV congestive heart failure, as defined by the New York Heart Association Classification of Congestive Heart Failure.
- History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
- Corrected QT interval (QTc) > 480 milliseconds
- Poorly controlled hypertension, defined as systolic blood pressure (SBP) of >= 140 millimeters of mercury(mmHg) or diastolic blood pressure (DBP) of >= 90 mmHg.
- Evidence of active bleeding or bleeding diathesis
- Uncontrolled diabetes mellitus (defined by a Hgb A1c >8) obtained within 14 days prior to registration. Optimal glucose control (Hgb A1c <= 8) must be achieved before registration and monitored during protocol treatment
- Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
- Unable or unwilling to discontinue use of prohibited medications
- Concurrent therapy given to treat cancer including treatment with an investigational agent or concurrent participation in another clinical trial involving anti-cancer investigational drug.
- Administration of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment.
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to everolimus
- Prior or current use of systemic anti-vascular endothelial growth factor (VEGF) inhibitors, cytokines or mechanistic target of rapamycin (mTOR) inhibitors (e.g. interferon, interleukin 2).
- Pregnant or nursing (lactating) women
- Women of child-bearing potential (WOCBP) must use highly effective methods of contraception during the study and 8 weeks after.
- Unable to obtain a contrast (gadolinium) based DCE MRI, including include patients with pacemakers, automatic implantable cardioverter/defibrillator (AICDs), non MRI compatible metallic implants or eGFR <30.
- Must not have received immunization with an attenuated live vaccine within seven days prior to registration nor have plans to receive such vaccination while on protocol treatment
- Must not be taking, nor plan to take while on protocol treatment, strong cytochrome P450 3A4 (CYP3A4) inhibitors, (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, fluvoxamine, nefazodone, nelfinavir, ritonavir) and/or strong CYP3A4 inducers (e.g. phenytoin, rifampin, rifabutin) within 14 days prior to randomization.
- History of another primary malignancy, with the exceptions of: non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for >= 3 years
- Childs-Pugh A-C liver disease (Appendix II)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (everolimus)
Patients will take 10 mg (1 tablet) of everolimus each day for 4 months
|
10 mg tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Tumor Volume Reduction Greater Than 25%
Time Frame: 12 months
|
Measuring the efficacy and tolerability of everolimus by measuring the number of patients with tumor volume reduction greater than 25% in sporadic AMLs as measured by DCE MRI
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of Everolimus in Patients With Sporadic AML
Time Frame: 12 months
|
Number of participants with treatment-related adverse events requiring dose reduction or study withdrawal as assessed by Common Toxicity Criteria for Adverse Effects (CTCAE v4.0)
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert G Uzzo, MD, PI
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 23, 2015
Primary Completion (Actual)
August 20, 2018
Study Completion (Actual)
August 20, 2018
Study Registration Dates
First Submitted
August 20, 2015
First Submitted That Met QC Criteria
September 1, 2015
First Posted (Estimate)
September 3, 2015
Study Record Updates
Last Update Posted (Actual)
December 15, 2022
Last Update Submitted That Met QC Criteria
December 13, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GU-070
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sporadic Angiomyolipomas (AMLs)
-
Novartis PharmaceuticalsCompletedSporadic Inclusion Body Myositis (sIBM)United States
-
UMC UtrechtCompleted
-
Regeneron PharmaceuticalsWithdrawnSporadic Inclusion Body Myositis
-
University of Southern DenmarkOdense University HospitalCompleted
-
University of LiegeWithdrawn
-
National Cancer Institute (NCI)RecruitingGenes | Sporadic ChordomaUnited States
-
University of Kansas Medical CenterCompletedInclusion Body Myositis | Sporadic Inclusion Body MyositisUnited States
-
Novartis PharmaceuticalsCompletedSporadic Inclusion Body MyositisUnited States
-
La-ser Europe LimitedUnknownSporadic Inclusion Body Myositis
-
University of California, IrvineNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)RecruitingInclusion Body Myositis | Sporadic Inclusion Body MyositisUnited States
Clinical Trials on Everolimus
-
Novartis PharmaceuticalsTerminatedHepatocellular CarcinomaHong Kong, Taiwan, Thailand
-
German Breast GroupNovartisTerminatedMetastatic Breast CancerGermany
-
The Netherlands Cancer InstituteActive, not recruitingNeuroendocrine CarcinomasNetherlands
-
Novartis PharmaceuticalsCompletedLymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
-
University of LuebeckTerminatedCoronary Artery DiseaseGermany
-
Guangdong Provincial People's HospitalNovartisUnknownNeuroendocrine Tumors | Carcinoid TumorChina
-
Novartis PharmaceuticalsCompletedGastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic SystemGermany
-
Novartis PharmaceuticalsTerminatedCarcinoma, Renal CellAustralia, Korea, Republic of
-
Centre Leon BerardSuspended
-
Leiden University Medical CenterUnknownHead and Neck CancerNetherlands